LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease

Genetic alterations in the <i>LRRK2</i> gene, encoding leucine-rich repeat kinase 2, are a common risk factor for Parkinson’s disease. How LRRK2 alterations lead to cell pathology is an area of ongoing investigation, however, multiple lines of evidence suggest a role for LRRK2 in lipid p...

Full description

Bibliographic Details
Main Authors:	Jasmin Galper, Woojin S. Kim, Nicolas Dzamko
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Biomolecules
Subjects:	LRRK2 lipid Parkinson’s disease glucocerebrosidase ceramide BMP
Online Access:	https://www.mdpi.com/2218-273X/12/11/1597

Similar Items

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
by: Laura J. Smith, et al.
Published: (2022-08-01)

Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
by: Nicoletta Plotegher, et al.
Published: (2019-04-01)

Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line
by: Clara Ruz, et al.
Published: (2022-06-01)

Rotenone Blocks the Glucocerebrosidase Enzyme and Induces the Accumulation of Lysosomes and Autophagolysosomes Independently of LRRK2 Kinase in HEK-293 Cells
by: Laura Patricia Perez-Abshana, et al.
Published: (2023-06-01)

LRRK2 and Proteostasis in Parkinson’s Disease
by: María Dolores Pérez-Carrión, et al.
Published: (2022-06-01)

Molecular Pathways Involved in LRRK2-Linked Parkinson’s Disease: A Systematic Review
by: Ailyn Irvita Ravinther, et al.
Published: (2022-10-01)

Changes in Liver Lipidomic Profile in G2019S-<i>LRRK2</i> Mouse Model of Parkinson’s Disease
by: Yaiza Corral Nieto, et al.
Published: (2023-03-01)

Generalized dystonia without Parkinsonism in an LRRK2 carrier
by: Lola Díaz-Feliz, et al.
Published: (2022-01-01)

Glial Nrf2 signaling mediates the neuroprotection exerted by Gastrodia elata Blume in Lrrk2-G2019S Parkinson’s disease
by: Yu-En Lin, et al.
Published: (2021-11-01)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
by: Eun-Mi Hur, et al.
Published: (2021-03-01)

Multiple-Hit Hypothesis in Parkinson’s Disease: LRRK2 and Inflammation
by: Diego Cabezudo, et al.
Published: (2020-04-01)

LRRK2 mediated Rab8a phosphorylation promotes lipid storage
by: Miao Yu, et al.
Published: (2018-02-01)

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
by: Alexia Polissidis, et al.
Published: (2020-06-01)

Pathological Functions of LRRK2 in Parkinson’s Disease
by: Ga Ram Jeong, et al.
Published: (2020-11-01)

Frequency of the LRRK2 G2019S mutation in late-onset sporadic patients with Parkinson’s disease
by: Hsin Fen Chien, et al.
Published: (2014-05-01)

QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease
by: Sebastián-Pérez Víctor, et al.
Published: (2019-02-01)

A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease
by: Li Shu, et al.
Published: (2019-01-01)

An Update on the Interplay between LRRK2, Rab GTPases and Parkinson’s Disease
by: Tadayuki Komori, et al.
Published: (2023-11-01)

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations
by: Adahir Labrador-Garrido, et al.
Published: (2023-10-01)

A pathway for Parkinson’s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain
by: Herschel S Dhekne, et al.
Published: (2018-11-01)

Parkinson’s Disease-Related Genes and Lipid Alteration
by: Milena Fais, et al.
Published: (2021-07-01)

Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease
by: Petar Podlesniy, et al.
Published: (2016-10-01)

Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo
by: Federica Albanese, et al.
Published: (2021-11-01)

LRRK2 G2019S, I2020T, R1441C GENE mutation analysis in patients with idiopathic Parkinsons in Turkey
by: Ahmet Adiguzel, et al.
Published: (2020-06-01)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
by: Darren M. O’Hara, et al.
Published: (2020-06-01)

Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease
by: Megan M. Senchuk, et al.
Published: (2021-04-01)

The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids
by: Asmaa Oun, et al.
Published: (2022-10-01)

Clinical Heterogeneity Among LRRK2 Variants in Parkinson's Disease: A Meta-Analysis
by: Li Shu, et al.
Published: (2018-09-01)

The function of Golgi apparatus in LRRK2-associated Parkinson’s disease
by: Yonghang Wei, et al.
Published: (2023-02-01)

Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery
by: Ali Esfandiary, et al.
Published: (2022-04-01)

Analysis of rs34637584 polymorphism in the LRRK2 gene in patients with Parkinson's disease
by: Kotlica Boba, et al.
Published: (2022-01-01)

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson’s Disease Model
by: Ruru Jia, et al.
Published: (2023-02-01)

Genetic and Environmental Factors Influence the Pleomorphy of <i>LRRK2</i> Parkinsonism
by: Vinita G. Chittoor-Vinod, et al.
Published: (2021-01-01)

Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment
by: Jillian H. Kluss, et al.
Published: (2022-08-01)

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
by: Robert K. Lesniak, et al.
Published: (2022-10-01)

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease
by: Elpida Tsika, et al.
Published: (2015-05-01)

Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease
by: Xiao Deng, et al.
Published: (2020-01-01)

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease
by: Maria Antonietta Casu, et al.
Published: (2020-02-01)

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson’s Disease
by: Genta Ito, et al.
Published: (2023-05-01)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
by: Kaela Kelly, et al.
Published: (2020-08-01)